Paper Details
- Home
- Paper Details
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Author: AkimaruShinji, ItoHidenori, KatsubeNobuo, MaegawaHitoshi, MarsalaMartin, NakaiKatsuhiko, TakenobuYoshifumi, TakimizuHideyuki
Original Abstract of the Article :
The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (I...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/s1098-8823(03)00044-3
データ提供：米国国立医学図書館（NLM）
OP-1206 alpha-CD: A Potential Oasis for Neuropathic Intermittent Claudication
Neuropathic intermittent claudication (IC) is a debilitating condition that affects the blood flow to the legs, causing pain and discomfort. This research explores the potential therapeutic effects of OP-1206 alpha-CD, a prostaglandin E1 (PGE1) analogue, in treating neuropathic IC. The study compares the effects of OP-1206 alpha-CD to those of nifedipine, ticlopidine, and cilostazol in a rat model of neuropathic IC.
A New Path: Exploring the Therapeutic Potential of OP-1206 alpha-CD
The study demonstrates that treatment with OP-1206 alpha-CD significantly improves walking dysfunction and spinal cord blood flow (SCBF) in the rat model of neuropathic IC. These findings suggest that OP-1206 alpha-CD may offer a promising therapeutic option for patients with neuropathic IC, providing a potential oasis of relief in the desert of symptoms.
Navigating the Desert of Treatment Options: A Potential Breakthrough
The authors emphasize the need for further research to translate these promising findings to clinical practice. The study highlights the potential of OP-1206 alpha-CD as a novel therapeutic agent for neuropathic IC. This research opens up new avenues for exploring the therapeutic potential of prostaglandin E1 analogues in treating this debilitating condition.
Dr. Camel's Conclusion
This research offers a glimpse into the potential of OP-1206 alpha-CD as a novel therapeutic agent for neuropathic intermittent claudication. The study demonstrates the drug's ability to improve walking dysfunction and spinal cord blood flow in a rat model, suggesting a potential path to relief for those suffering from this debilitating condition. While further research is needed to confirm these findings in human clinical trials, this study provides a valuable roadmap for exploring the therapeutic potential of prostaglandin E1 analogues in treating neuropathic IC.
Date :
- Date Completed 2004-04-29
- Date Revised 2019-11-08
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.